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Abstract
Fibroblast growth factor (FGF) signaling contributes to failure of remyelination in multiple sclerosis, but targeting
this therapeutically is complicated by its functional pleiotropy. We now identify FGF2 as a factor up-regulated
by astrocytes in active inflammatory lesions that disrupts myelination via FGF receptor 2 (FGFR2) mediated
activation of Wingless (Wnt) signaling; pharmacological inhibition of Wnt being sufficient to abrogate inhibition
of myelination by FGF2 in tissue culture. Using a novel FGFR1-selective agonist (F2 V2) generated by deleting the
N-terminal 26 amino acids of FGF2 we demonstrate polarizing signal transduction to favor FGFR1 abrogates FGF
mediated inhibition of myelination but retains its ability to induce expression of pro-myelinating and immunomodulatory
factors that include Cd93, Lif, Il11, Hbegf, Cxcl1 and Timp1. Our data provide new insights into the mechanistic basis of
remyelination failure in MS and identify selective activation of FGFR1 as a novel strategy to induce a neuroprotective
signaling environment in multiple sclerosis and other neurological diseases.
Keywords: Multiple sclerosis and Neuroinflammation, Remyelination, Neuroprotection, Neuroinflammation,
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Introduction
Multiple sclerosis (MS) is a chronic neurodegenerative
disease of the central nervous system (CNS) in which re-
peated episodes of inflammatory demyelination result in
persistently demyelinated plaques of gliotic scar tissue
associated with varying degrees of axonal injury and loss.
This axonal pathology is the underlying cause of chronic
disability in MS and is intimately associated with demye-
lination. Loss of myelin in the inflammatory milieu of an
MS lesion not only increases axonal susceptibility to in-
flammatory mediators per se [63] but also disrupts meta-
bolic support provided by myelinating oligodendrocytes
[28, 50]; a combination of effects that result in profound
axonal energy deficits that compromise the functional
and structural integrity of affected axons [12, 26, 81]. In
experimental models these detrimental effects of demye-
lination on axonal health are mitigated by remyelination
carried out by oligodendrocytes derived from oligodendro-
cyte progenitor cells (OPC) [21, 43, 52, 93]. However, in
MS this endogenous repair mechanism frequently fails
leaving demyelinated axons increasingly vulnerable to in-
flammatory and metabolic stress [27].
Why remyelination fails in MS remains unclear, but it
is generally believed to involve factors that disrupt the
differentiation of OPC into myelination-competent oli-
godendrocytes [15, 48, 73, 84]. These include changes af-
fecting growth factor availability and composition of the
extracellular matrix, inhibitory signals derived from mye-
lin debris, inappropriate re-expression of developmental
signaling pathways, and effects due to ageing [74]. How-
ever, the initial events that disrupt OPC differentiation
in the inflammatory milieu of an MS lesion remain ob-
scure. Recent studies suggest this may involve members
© The Author(s). 2019 Open Access This article is distributed under the terms of the Creative Commons Attribution 4.0
International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and
reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to
the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver
(http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
* Correspondence: kat.thuemmler@gmail.com
†Katja Thümmler and Eran Rom contributed equally to this work.
1Institute of Infection, Immunity and Inflammation, University of Glasgow,
120 University Place, Glasgow G12 8TA, UK
Full list of author information is available at the end of the article
Thümmler et al. Acta Neuropathologica Communications           (2019) 7:212 
https://doi.org/10.1186/s40478-019-0864-6
of the fibroblast growth factor (FGF) family, in particular
FGF2 [18, 39, 54, 69] which acts as a negative regulator
of (re) myelination in the adult CNS [10, 53].
FGF2 plays important roles in CNS development dur-
ing which it influences proliferation, speciation and mi-
gration of neural progenitor cells [85]. It continues to be
expressed at low levels by astrocytes and some neurons
in the adult CNS, but is rapidly up regulated in response
to CNS injury [58]. The pathophysiological significance
of this response is unclear as FGF2 is functionally pleio-
tropic, experimental studies demonstrating that in
addition to its detrimental effects on remyelination it
also supports OPC proliferation and migration [2, 9, 11],
as well as mediating a neuroprotective response which
reduces clinical deficits and tissue damage in animal
models of MS [66, 68]. Any attempt to modulate FGF2
signaling to enhance lesion repair must take this func-
tional pleiotropy into account and aim to suppress its
detrimental effects on remyelination whilst retaining its
“neuroprotective” potential.
Canonical members of the FGF family such as FGF2
signal via a small family of transmembrane tyrosine ki-
nases encoded by Fgfr1, Fgfr2, Fgfr3 and Fgfr4 which
activate a variety of intracellular signaling pathways in-
cluding RAS-MAPK, PI3K-AKT, PLCγ, and signal trans-
ducer and activator of transcription (STAT) (reviewed in
[57]). Previous studies demonstrate the biological out-
come of FGF2 signaling within the oligodendrocyte
lineage is determined by stage-specific changes in recep-
tor expression; activation of FGFR1 driving OPC prolif-
eration, whilst subsequent and sequential expression of
FGFR3 and FGFR2 on oligodendrocytes is associated
with inhibition of myelin protein expression and de-
differentiation [25]. But does this concept extend to the
complex environment of the CNS in which these recep-
tors are also expressed by astrocytes, glia, neurons,
microglia and endothelial cells? Specifically, would skew-
ing signal transduction to favour FGFR1 suppress its
detrimental effects of myelination whilst retaining its
ability to support OPC proliferation and generate a
broadly „neuroprotective “signaling environment.
We report expression of FGF2 by astrocytes correlates
with inflammatory activity in MS lesions and present
data demonstrating this inhibits myelination via FGFR2-
mediated activation of Wingless (Wnt)-signaling; pharma-
cological inhibition of Wnt signal transduction being suffi-
cient to abrogate the inhibition of myelination by FGF2 in
tissue culture. Skewing signal transduction to favour
FGFR1 abolishes this detrimental effect on OPC differenti-
ation, but retains the ability of FGF2 to act as an OPC
mitogen and induce expression of “neuroprotective”
factors with anti-inflammatory, neuroprotective and pro-
myelinating properties. Our data demonstrate the
biological outcome of FGF2 signaling in the CNS is
determined at the level of FGFR usage and raises the
exciting possibility FGFR1-specific agonists may provide a
new approach to enhance lesion repair in the CNS.
Materials and methods
Generation of F2 V2 and FGFR specificity assay
NdeI and BamHI sites were appended to human FGF2
cDNA by PCR and the resulting fragment was cloned in
NdeI/BamHI digested pET9a. A deletion mutant of
FGF2 lacking the N-terminal 26 amino acids of the na-
tive protein (F2 V2) was designed and generated by
oligonucleotide directed PCR mutagenesis of





The resulting pET9aFGF2Δ26 was expressed in
BL21DE3 bacteria and the product (F2 V2) purified on
heparin-Sepharose column (US patent WO2008/
038287).
To define receptor specificity, the mouse myeloid pro-
genitor cell line FDCP-1 was cultured in ISCOVES
medium [(Gibco, Rockville, MD, USA) supplemented
with 10% FCS, penicillin, streptomycin, glutamine and
0.1 ng/ml IL3] and transfected with full length human
FGFR1, 2, 3 or 4 (FDCP-FGFR1, FDCP-FGFR2, FDCP-
FGFR3, FDCP-FGFR4). Transfected FDCP-1 cells were
plated at a density of 2 × 104 cells/well in 96 well plates
in the same medium, but substituting IL3 with 10 ng/ml
of either FGF2 or F2 V2. Proliferation was determined
48 h later using XTT Cell Proliferation Assay (Biological
Industries, Beit Haemek, Israel). The FGFR specific hu-
man scFv antibodies PRO-001 (FGFR3 specific) and
PRO-007 (FGFR2/3 specific), generated using phage dis-
play libraries [62] and produced by bacterial fermenta-
tion at Fibron Ltd. Israel were used as described
previously [80].
Human tissues: in situ hybridization
In situ hybridization studies were carried out using fresh
frozen tissue samples provided by the UK Multiple
Sclerosis Tissue Bank (UK Multicentre Research Ethics
Committee, MREC/02/2/39). Synthetic digoxigenin-
labelled riboprobes (cRNA) were generated from recom-
binant pCRTMII-Topo® plasmid containing a 691 bp
cDNA insert of human FGF2 (sequence: 5′-2985 to
3675–3′). Transcription was done from both sides with
either SP6 or T7 RNA polymerase, generating antisense
or sense (control) cRNA probes. In situ hybridization
was performed on cryosections of freshly frozen tissues
as described previously [35, 71]. In situ hybridization sig-
nals were revealed by alkaline phosphatase with BCIP
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(5-bromo- 4-chloro-30-indolyphosphate) and NBP (ni-
tro-blue tetrazolium) as substrate.
Immunohistochemistry and immunofluorescence of
human tissues
Tissue sections were fixed in 4% PFA for 15 min and
then washed twice with PBS. Thereafter sections were
treated with 0.6% hydrogen peroxide in methanol for 30
min and with blocking buffer (1% normal donkey serum,
0.1% TritonTM X-100, 0.05% Tween) for 1 h. Sections
were then incubated with the following primary anti-
bodies overnight at 4 °C: rabbit anti-OLIG2 (1:500,
Millipore), rabbit anti-GFAP (1:2000, DakoCytomation),
mouse anti-MOG (1:500, Z12) and rat anti-CD68 (1:500,
Abcam). Sections were washed with PBS and then sec-
ondary biotinylated antibodies (Vector Laboratories, 1:
500) were applied for 2 h at room temperature, followed
by ABC complex reagent (Vector Labs) for 30 min.
Colour reaction was performed with 3-amino-9-ethylcar-
bazole. Luxol Fast blue and haematoxylin and eosin
staining were performed according to standard proto-
cols. Immunofluorescent stainings were made after
blocking in 5% NDS, 1% FSG, 0.3M glycine for 2 h. Sec-
tions were then incubated with rabbit anti-FGF2 (1:500,
Abbiotec), rabbit anti-FGFR1 (1:500, Abbiotec) and/or
mouse anti-GFAP (1:1000, Sternberger Monoclonals
Inc.). Autofluorescence was quenched by incubating the
slides 1 h in 10 mM CuSO4 in 50mM Ammonium acet-
ate buffer (pH 5.0). Sections were washed in PBS and in-
cubated with secondary antibodies (1:500, Jackson
Immunoresearch Europe Ltd.) and 1:10000 DAPI for 2 h
at RT. Sections were then washed with PBS and
mounted with Fluorosave (MerckMillipore). For each
data point the average total intensity of 10 randomly
taken pictures was measured, log2 transformed and nor-
malized to the corresponding value of the normal
appearing white matter (within the same patient).
Cell and tissue culture
In vitro myelinating cultures were established from em-
bryonic day 15.5 rat spinal cords (Sprague Dawley) or
embryonic day 13.5 mouse spinal cords (C57BL/6 J) as
described previously [22, 51, 78]. Cultures were main-
tained at 37 °C/7% CO2 and fed three times a week by
replacing half the culture medium with fresh differenti-
ation media. Twelve days later insulin was omitted from
the culture medium to promote myelination. Cultures
were treated with the following factors as detailed in the
text: recombinant human F2 V2 (10, 50 or 100 ng/ml),
FGFR3 blocking antibody PRO-001 (10 μg/ml) and
FGFR2&3 blocking antibody PRO-007 (5 μg/ml) (all pro-
vided by ProCore Biomed. Ltd. Israel); human FGF2 (10,
50 or 100 ng/ml, Peprotech); 20 μM Tankyrase Inhibitor
XAV939 (Tocris).
Neurosphere-derived astrocytes were generated as de-
scribed previously [51] by dissociating striata of post-
natal day 1 Sprague-Dawley rats or C57BL/6 J mice and
resuspending them in 20ml neurosphere media (see
[51]) supplemented with 20 ng/ml mouse submaxillary
gland epidermal growth factor (EGF, R&D Systems) in a
75 cm3 tissue culture flask. Triturated neurospheres were
then plated on PLL coated cover slips in low glucose
DMEM supplemented with 10% foetal bovine serum and
cultured until they formed a confluent monolayer.
OPCs were immunopurified from P1 rat cortex using
an anti-A2B5 MicroBead Kit (Miltenyi Biotec, Germany)
according to manufacturer’s instructions. Purified A2B5+
progenitors were plated on PLL coated cover slips in
Basal Chemically Defined medium (DMEM, 4mML-
glutamine, 1 mM sodium pyruvate, 0.1% BSA, 50 μg/ml
Apo-transferrin, 5 μg/ml insulin, 30 nM sodium selenite,
10 nM D-Biotin and 10 nM hydrocortisone) containing
50 ng/ml PDGF and 50 ng/ml FGF2 (both Peprotech) at
a density of 1–2 × 104 cells / cm2. After 2 DIV PDGF/
FGF2 was withdrawn and cells were allowed to differen-
tiate for 6 days in modified Sato’s medium ([8]; DMEM
containing 4500mg/L glucose, 2 mM glutamine, 5000 U/
ml penicillin, 5 μg/ml streptomycin, 10 μg/ml insulin,
100 μg/ml apotransferrin, 16.1 μg/ml putrescine, 60
ng/ml progesterone, 30 nM sodium selenite, 0.4 μg/ml
triiodo-L-thyronine, 0.4 μg/ml L-thyroxine T4, and 0.1
mg/ml BSA) in the absence or presence of FGF2
(100 ng/ml) or F2 V2 (100 ng/ml). Cells were fed twice
a week by replacing half the culture supernatant with
fresh media.
Immunofluorescence microscopy
Cultures were fixed in 4% paraformaldehyde (PFA) for
20 min at RT, permeablised with 0.5% Triton-X in PBS
for 15 min and blocked for 30 min in PBS/10% Horse
serum/1% bovine serum albumin. Primary antibodies
were applied for 45 min and washed in PBS before sec-
ondary antibodies were applied (15 min) in the dark.
Thereafter cover slips were washed with PBS followed
by distilled water and mounted with Mowiol 4–88
(Calbiochem, UK). The following primary antibodies
were used: SMI-31 (1:1500, mouse IgG1, Abcam), Z2 (1:
500, MOG-specific, mouse IgG2a, [60]), O4 (1:500,
mouse IgM, R&D Systems), Olig2 (1:1000, rabbit IgG,
Millipore), AA3 (1:100, PLP/DM20 specific, rat IgG,
[87]). Species and isotype specific secondary antibodies
labelled with Alexa Fluor 488 or Alexa Fluor 568 (Invi-
trogen) were used at 1:400. OPC cell proliferation was
analyzed using the Click-iT EdU Alexa Fluor 594 Kit
(Invitrogen) following the manufacturer’s instructions
after incubation with EdU for 72 h. EdU labelled cultures
were then co-stained with DAPI and lineage-specific
markers. For quantitative analysis 10 random images
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from each of three coverslips were taken at 10× magnifi-
cation (neurite density and myelination) or 20x magnifi-
cation (cell counts) using an Olympus BX51 fluorescent
microscope and Image-Pro (Media Cybernetics) or
Ocular software (QImaging). Representative confocal
images were obtained at 63x magnification using a Zeiss
LSM 710 inverted confocal microscope and Zen Black
software. Neurite density, myelination and cell counts
were quantified using CellProfiler cell image analysis
software [14]. The pipelines developed for this study are
available at https://github.com/muecs/cp.
RNA extraction and microarray analysis
RNA was extracted using the Qiagen RNeasy Micro kit
according to manufacturer’s instructions. RNA quality
and integrity was checked using the Agilent Bioanalyzer
6000 Nano LabChip platform. RNA was then used for
microarray expression analysis and quantitative reverse
transcription (qRT)-PCR. The total RNAs were
processed and labelled with biotin using Ambion® WT
Expression Kit following the Affymetrix GeneChip® WT
Terminal Labeling and Hybridization protocol. The
processed RNAs were hybridized to Affymetrix
GeneChip® Rat Gene 2.1 ST Arrays using manufacturer’s
protocols for using the Fluidics Station 450. The hybrid-
ized arrays were scanned on the Affymetrix GeneTitan
Scanner. Data analysis was carried out in Partek Genom-
ics Suite (version 6.6, Partek Inc., St. Louis, MO, USA)
software. Control (CTR) and Treatment (FGF) groups
were generated with four replicates per group.
This dataset has been deposited in the Gene Expres-
sion Omnibus database: https://www.ncbi.nlm.nih.gov/
geo/query/acc.cgi?acc=GSE65466.
The probe set level data were normalized using
GCRMA normalization method and summarized to
transcript cluster level using one-Step Tukey’s Biweight
method. Differential expression analysis was carried out
by performing one-way ANOVA test on the normalized
expression values. Differentially expressed gene lists
were generated based on the ANOVA with fold change
> ± 1.4 at a FDR adjusted p-value of < 0.05 and analysed
in Partek Pathway for enriched pathways utilizing the
KEGG (Kyoto Encyclopedia of Genes and Genomes)
database for rat. Hierarchical cluster analysis of differen-
tially expressed genes (FDR adjusted p-value of < 0.05),
differential expression profile analysis and gene ontology
enrichment was performed with Searchlight2 [19]. Using
the array background, three differential expression work-
flows (control vs F2 V2, control vs FGF2 and F2 V2 vs
FGF2), and one multiple differential expression workflow
(combining all three differential expression comparisons)
were generated. For specific differential expression
profiles the gene ontology enrichment was performed
using a standard hypergeometric test with Benjamini-
Hochberg multisample correction (significance at p-
BH < 0.05). In each case the biological process database
was used (http://geneontology.org/). All other parame-
ters were left to default.
Quantitative real-time PCR
Changes in expression of selected genes were validated
using RNA obtained from myelinating cultures (DIV 18)
grown in the presence or absence of FGF2 or F2 V2 for
24 h. Following RNA extraction, cDNA was synthesized
using the Qiagen QuantiTect® Reverse Transcription Kit
following the manufacturer’s instructions. Cycling pa-
rameters were as follows: first cycle (DNA wipeout step)
42 °C for 2 min, after adding reverse transcriptase, reac-
tion buffer and primer mix second cycle: 42 °C for 20
min, then 3min for 95 °C. Real-time PCR was performed
using 1X SYBR Green master mix (Applied Biosystems),
10 ng cDNA template and 50 pmol/μl of each primer.
Primers were designed using the NCBI nucleotide data
base and Primer 3 software (http://biotools.umassmed.
edu/bioapps/primer3_www.cgi) [67]. Primer sequences
were checked with BLAST (http://blast.ncbi.nlm.nih.gov/
Blast.cgi) and were purchased from IDT.
The reaction was amplified in an Applied Biosystems
Fast Real-Time PCR System (ABI 7500) using the fol-
lowing cycle settings: 50 °C for 5 min, 95 °C for 10 min,
followed by 40 cycles of 95 °C for 15 s, 60 °C for 1 min,
and a final dissociation step at 95 °C for 15 s. Melt curve
analysis was then performed between 75 and 99 °C in
1 °C increments. The comparative CT method (or the
2-ΔCT method) [72] was used to determine differences in
gene expression. For statistical analysis, a one-way
ANOVA was used on the mean ΔCT for each experi-
mental repeat to test for significant changes compared
to untreated cultures and a paired t-test to test for sig-
nificance in fold changes of FGF2 vs F2 V2.
Protein assays
Mouse myelinating cultures (days in vitro - DIV18) or
mouse neurosphere-derived astrocytes were cultured in
the presence of 100 ng/ml FGF2 or F2 V2 and after 3
days supernatants were harvested. Protein concentra-
tions of CXCL1 and MMP3 in the supernatants were
measured using mouse CXCL1 or MMP3 Quantikine
ELISA kits (both R&D Systems) according to the manu-
facturer’s instructions. TIMP1 protein levels were
assessed by Proteome Profiler (Mouse Cytokine Array
Panel A, R&D Systems), pixel densities were converted
into arbitrary units using TotalLab Quant software.
Statistics
All statistics were calculated with GraphPad Prism
(GraphPad Software Inc.; La Jolla, CA, USA) using
paired t-tests or one-way ANOVA (Tukey post-test
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unless stated otherwise) as specified in the text. A p-
value < 0.05 was considered statistically significant, with
p < 0.001 ***; p < 0.01 **; p < 0.05 *; n.s. = not significant.
Results
Astrocytes up-regulate expression of FGF2 in active
multiple sclerosis lesions
Expression of FGF2 was investigated in lesions and nor-
mal appearing white matter (NAWM) from seven cases
of multiple sclerosis by immunohistochemistry and in
situ hybridization (Fig. 1, Additional file 1). FGF2 im-
mune reactivity was most prominent in demyelinated le-
sions where it was associated with extracellular staining
suggestive of local release and binding of FGF2 to the
extracellular matrix ([47], Fig. 1c, d). Immune fluores-
cence microscopy revealed these lesions contained large
numbers of FGF2+ GFAP+ astrocytes, whereas only oc-
casional FGF2+ astrocytes were present in NAWM. To
confirm this represented de novo synthesis of FGF2 we
combined in situ hybridization for Fgf2 with immunohis-
tochemistry for GFAP and OLIG2. Fgf2 expression was
clearly enhanced in lesions (Fig. 1f) primarily in GFAP+
astrocytes (Fig. 1g). However, occasional Fgf2+ OLIG2+
cells were also present (Fig. 1h); an observation in agree-
ment with reports FGF2 can be expressed by OPC [90].
FGF2 may be expressed by some neuronal subpopula-
tions and occasional microglia/macrophages [18, 33].
However our data are consistent with astrocytes being
the dominant source of FGF2 in these lesions. This in-
terpretation is supported by semi-quantitative analysis of
immune reactivity for FGF2 and GFAP that identified a
strong positive correlation between these parameters
(r = 0.719; p < 0.001) (Fig. 1i). To determine if FGF2 ex-
pression also correlated with inflammatory activity and/
or demyelination, immune reactivity for CD68 was used
as a proxy for inflammation and LFB histochemistry and
MOG immune reactivity were used to assess demyelin-
ation. This revealed FGF2 immune reactivity correlated
positively with inflammation (CD68 immune reactivity:
r = 0.298, p = 0.047) and negatively with myelination
(MOG immune reactivity: r = − 0.296, p = 0.048; LFB
histochemistry: r = − 0.385, p = 0.010) (Fig. 1i). Inflam-
matory demyelination in MS is therefore associated with
increased expression of FGF2 by astrocytes.
Restricting signal transduction to FGFR1 dissociates
inhibition of myelination by FGF2 from its mitogenic
potential
Having confirmed FGF2 was available to influence lesion de-
velopment we then explored its pathophysiological signifi-
cance in tissue culture. As stated previously FGF2 is
pleiotropic and in addition to its detrimental effects on oligo-
dendrocyte differentiation and (re) myelination [25, 79] [53]
is neuroprotective in EAE [66, 68]. The mechanistic basis of
this neuroprotective response is poorly understood but may
include effects that enhance neurogenesis, proliferation,
mobilization and recruitment of OPC, and/or limit immune
cell recruitment across the blood brain barrier [3, 66, 68].
As previous studies indicate the mitogenic potential of
FGF2 is FGFR1 dependent [25] we investigated the effects
of F2 V2, a novel FGFR1-selective agonist, on oligoden-
drogenesis and myelination in cultures derived from em-
bryonic spinal cord; an in vitro model that replicates the
cellular complexity of the CNS and allows identification of
direct and “off target” effects on OPC biology [51]. F2 V2
was generated by deleting the N-terminal 26 amino acids
of FGF2, a domain that contributes to promiscuity of re-
ceptor recognition by other FGF family members [7, 41].
In the case of FGF2 this deletion generated a mutant that
retained the ability of the native protein to activate FGFR1,
but reduced its ability to induce FGFR2-, FGFR3- and
FGFR4-dependent proliferation in FGFR transfected re-
porter cells by approximately 90% (Additional file 2).
In myelinating cultures FGF2 and F2 V2 induced com-
parable increases in OLIG2+ and O4+ cell numbers indi-
cating these effects were FGFR1-dependent, but only
FGF2 inhibited myelination (Fig. 2a-c). Activation of
FGFR1 is therefore sufficient to drive OPC proliferation
and initiate oligodendrocyte differentiation but in isolation
has no significant effect on myelination. This implies in-
hibition of myelination by FGF2 is dependent on signal
transduction via FGFR2 and/or FGFR3 (expression of
FGFR4 in the CNS is minimal [90];). This was confirmed
using FGFR3- and FGFR2/3-specific neutralizing anti-
bodies [25, 62, 80]. FGF2-mediated inhibition of myelin-
ation was unaffected by the FGFR3-specific antibody, but
was abrogated significantly by the FGFR2/FGFR3-specific
reagent demonstrating inhibition of myelination by FGF2
in this model system is FGFR2-dependent (Fig. 2d).
We then compared the effects of FGF2 and F2 V2 on
oligodendrogenesis in the absence of other cell types using
immunopurified A2B5+ progenitors (Fig. 2e-g). The mito-
genic potential of FGF2 and F2 V2 was virtually identical
(Fig. 2e, f), but unlike the situation in myelinating cultures
they were unable to expand the number of O4+ oligoden-
drocytes, an effect associated with reduced differentiation
of OPC’s into more mature PLP+ and MOG+ oligodendro-
cytes (Fig. 2g). This suggests FGFR1 signaling in myelinat-
ing cultures is not only mitogenic for OPC, but also
induces an “off-target” response that allows them to drop
out of cell cycle and differentiate into O4+ oligodendro-
cytes, a necessary step towards successful (re)myelination.
OPC proliferation and inhibition of myelination are
associated with distinct FGFR-specific transcriptional
profiles
To identify how FGF2 and F2 V2 induce these FGFR-
dependent effects on OPC proliferation/differentiation
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and myelination we performed a gene microarray study
in myelinating cultures. Hierarchical cluster analysis of
9637 transcripts with significant changes in expression
induced by either ligand (FDR-adjusted p < 0.05) re-
vealed a considerable overlap in the transcriptional
response to the two ligands (Fig. 3a). FGF2 and F2 V2
differentially regulated 3793 (1983 up; 1810 down) and
1812 (1089 up; 723 down) transcripts, respectively (fold
change ≥ +/− 1.4; Fig. 3a; Additional file 3). We reasoned
the 1623 transcripts differentially regulated by both
FGF2 and F2 V2 define a FGFR1-dependent
transcriptome that would reflect these ligands’ ability to
enhance OPC proliferation. This interpretation was sup-
ported by differential expression profile and gene ontol-
ogy enrichment analysis which revealed the most highly
enriched GO terms associated with FGFR1 signaling
were related to cell cycle and DNA replication (Fig. 3b,
Additional file 7: Table S1). Conversely, we reasoned the
2170 transcripts only regulated in response to FGF2 de-
fined a transcriptome containing components respon-
sible for FGFR2-dependent inhibition of myelination
(Additional file 3). This was also supported by gene
Fig. 1 FGF2 is up-regulated in astrocytes of subcortical multiple sclerosis lesions. Fluorescence immunostaining for FGF2 and GFAP of NAWM (a)
and active multiple sclerosis lesion (b) show strong FGF2 expression in the lesion. FGF2 expression co-localizes with GFAP (c). This finding is
supported by immunohistochemistry of FGF2 expression in multiple sclerosis lesion (d). Demyelinating lesion is indicated by reduced Fast Luxol
Blue staining around the blood vessel (e). In situ hybridization depicts Fgf2 transcripts within active lesion (f) mainly in GFAP-positive cells (g,
arrows), and only rarely and weakly in Olig2-positive cells (h, arrow). Most of the Olig2-positive cells do not express FGF2 (h, arrowhead). Note,
ISH is weaker after immunohistochemistry. Magnifications a, b, g and h: 40x; d-f: 10x; bv: blood vessel, c: scale bars represent 20 μm. i
Quantification of FGF2 intensity in correlation to GFAP, MOG, CD68 and LFB shows positive correlation with GFAP and inflammation (CD68) and
negative correlation with myelin reactivity (LFB and MOG). Ten randomly taken images from at least 3 areas of interest per multiple sclerosis
patient (n = 7 patients) were analyzed and normalized to the corresponding values in the NAWM of the patient. Data was log2 transformed and
Pearson correlation over all cases was calculated
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Fig. 2 N-terminal truncation of FGF2 abrogates its ability to inhibit myelination without disrupting its mitogenic activity. a Myelinating rat CNS
cultures were treated with 100 ng/ml FGF2 or F2 V2 for 10 days (DIV18–28); provided are representative images demonstrating the differential
effects of FGF2 and F2 V2 on myelination rates determined by MOG pos. sheets. Bars represent 100 μm. b In cultures treated with FGF2 or F2 V2
for 10 days FGF2, but not F2 V2 significantly inhibits myelination as determined by percentage of MOG pos. sheets/ SMI31 (one-way ANOVA). c
Both FGF2 and F2 V2 significantly increase the number of Olig2+ and O4+ cells (one-way ANOVA). d Blocking antibodies directed towards FGFR3
(PRO-001) or towards FGFR2/3 (PRO-007) have different effects on the inhibition of myelination by FGF2, with blocking FGFR2/3 abrogating the
effect of FGF2 (one-way ANOVA, p < 0.01 for FGF2 vs FGF2 + αFGFR2/3). e, f Proliferation of immunopurified A2B5+ OPCs in the presence or
absence of FGF2 or F2 V2 (100 ng/ml). e Both FGF2 and F2 V2 act as strong mitogens on purified OPCs cultured for 6 days in differentiation
media (modified Sato’s medium) as cell numbers (DAPI staining) significantly (one-way ANOVA) increase 3.4 or 2.7 times after treatment with
FGF2 or F2 V2 respectively. f A2B5+ progenitors were maintained in modified Sato’s medium in the presence of FGF2 or F2 V2 for 72 h and
proliferation was determined by EdU incorporation. There is no significant difference in the ability of FGF2 and F2 V2 to maintain OPC
proliferation (one-way ANOVA). g A2B5+ progenitors were cultured for 6 days in modified Sato’s medium and the amount of O4+, PLP+ or MOG+
pos. cells (% of DAPI) was quantified. FGF2 treatment significantly reduced O4 expression (p < 0.05, one-way ANOVA) and almost abolished PLP
and MOG expression (p < 0.001 for both markers, one-way ANOVA). Data are presented as means ± SEM from at least 3 independent
experiments; * p < 0.05; ** p < 0.01; *** p < 0.001; ns – not significant
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Fig. 3 (See legend on next page.)
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ontology enrichment analysis which demonstrated this
“non-FGFR1 associated” transcriptome was enriched in
GO terms related to glial differentiation including “Glio-
genesis”, “Glial Cell Differentiation”, “Astrocyte Differen-
tiation” and “Oligodendrocyte Differentiation” (Fig. 3b).
FGFR2 mediated inhibition of myelination is Wnt
dependent
To identify pathways contributing to FGFR2-dependent
inhibition of myelination we then focused on a third
transcriptional profile consisting of those genes more
up-regulated by FGF2 than F2 V2 (Fig. 3b, Additional
file 7: Table S3). This profile was significantly enriched
in 39 GO terms including three associated with
Wingless (Wnt) signaling (Additional file 4 and Add-
itional file 7). This was significant as Wnt signaling not
only contributes to developmental control of myelin-
ation, but is also implicated in failure of remyelination in
MS [23, 49, 75]. We therefore performed an additional
analysis to test this association using an alternative
software package (Partek Genomics Suite and Partek
Pathway version 6.6). This identified 1047 transcripts
differentially regulated by FGF2 relative to F2 V2 (528
down, 519 up; FDR-adjusted p < 0.05 and +/− 1.4 fold
change). These transcripts were significantly enriched in
44 KEGG pathways that again included Wnt signaling
(Additional file 5). Validation of our array data for se-
lected components of the Wnt signaling pathway by
qPCR (Additional file 6) provided additional evidence
that inhibition of myelination by FGF2 was associated
with Wnt signaling. We therefore tested the effect of dis-
rupting Wnt signaling on FGF2-mediated inhibition of
myelination using XAV939, a tankyrase 1 and 2 inhibitor
that disrupts Wnt signaling by stabilizing the β-catenin
destruction complex. XAV939 abrogated the ability of
FGF2 to inhibit myelination (Fig. 3d; FGF2 versus
FGF2 + XAV939, p < 0.05; Newman-Keuls post-test)
demonstrating inhibition of myelination by FGF2 is
dependent on activation of Wnt signaling. In contrast,
XAV939 had no effect on basal levels of myelination,
nor did it influence FGF2 induced (FGFR1-dependent)
OLIG2+ cell proliferation (Fig. 3c-e).
FGFR1 supports induction of pro-myelinating and
neuroprotective factors
Having demonstrated the “FGFR1-associated” F2 V2
transcriptome was enriched in pathways associated with
cell cycle and DNA replication (Fig. 3b), we explored
this data set for evidence it might also support OPC dif-
ferentiation or mediate other potentially neuroprotective
effects. We identified multiple transcripts encoding
products with pro-myelinating and/or immunomodula-
tory effects including leukaemia inhibitory factor (LIF
[76];), interleukin 11 (IL11 [38, 91];); heparin-binding
EGF-like growth factor (HB-EGF [1, 13, 59];), chemokine
(C-X-C motif) ligand 1 (CXCL1 [56];), tissue inhibitor of
metalloproteinase 1 (TIMP1 [55];) and Cluster of
Differentiation 93 (CD93 [40];) (Table 1). Conversely, F2
V2 was unable to replicate the ability of FGF2 to up-
regulate expression of matrix metalloproteinases (MMP)
contributing to blood–brain barrier breakdown in in-
flammatory and ischemic disorders [65, 89] (Mmp13:
FGF2 fold change + 28; Mmp3: FGF2 fold change + 6.8;
F2 V2 fold change < +/− 1.2 for both genes) (Table 1).
These observations were validated at the protein level
by assaying CXCL1, MMP3 and TIMP1 in supernatants
from mouse myelinating cultures (Fig. 4a-c). F2 V2
retained the ability of FGF2 to increase CXCL1 and
TIMP1 levels confirming these are at least in part
FGFR1-dependent responses, but induced no significant
(See figure on previous page.)
Fig. 3 Transcriptional profiling identifies a fingerprint associated with FGF2-mediated inhibition of myelination, which is dependent on Wnt
signaling. Myelinating rat CNS cultures were treated with 100 ng/ml FGF2 or F2 V2 for 24 h at DIV18 and gene expression was analyzed by
performing an Affymetrix rat gene array. a Hierarchical cluster analysis of the 9637 transcripts with FDR-adjusted p < 0.05 for any of the treatments
(FGF2 or F2 V2) was performed. Shown are expression values for the four technical replicates in each group; gene expression level is represented
by colour intensity (high expression in red, low expression in blue). Expression values were scaled using Z-score. 3793 or 1812 transcripts were
differentially regulated by FGF2 or F2 V2 (fold change > + 1.4; FDR-adjusted p < 0.05), in a comparative analysis of these genes 1623 transcripts are
regulated in a similar manner by FGF2 (dark grey intersection) and 2170 are regulated selectively by FGF2. b Three distinct transcriptional profiles
are plotted, with a subset of 1582 transcripts significantly up-regulated by both FGF2 and F2 V2 (top panel – Additional file 7: Table S1), 486
transcripts specifically down-regulated by FGF2 but not regulated by F2 V2 (middle panel – Additional file 7: Table S2) and 1026 transcripts
specifically more up-regulated by FGF2 (lower panel – Additional file 7: Table S3). Shown are the meta-gene expression, heatmaps and 10 most
significantly enriched GO terms for each of the three signature profiles. This revealed a mitogenic profile in the genes up-regulated by both FGF2
and F2 V2 (Additional file 7: Table S1), a signature for glia cell differentiation in the genes specifically down-regulated by FGF2 (Additional file 7:
Table S2) and a profile identifying pathways potentially contributing to the inhibition of myelination by FGF2 (Additional file 7: Table S3).
Myelinating rat CNS cultures were treated with 100 ng/ml FGF2 in the absence or presence of a specific inhibitor of the Wnt pathway (20 μM
Tankyrase Inhibitor XAV939) for 10 days at DIV18 and myelination rates (MOG positive myelin sheets) were analyzed (c, d) or proliferation of
oligodendrocyte lineage cells was analyzed after 3 days of treatment by incorporation of EDU in Olig2 positive cells (e). c Representative images
for untreated (Control) cultures or cultures treated with FGF2 or FGF2 & XAV939 are shown, scale bars represent 100 μm. (d, e) shown are
mean + SEM from at least 4 independent experiments and p-values for one-way ANOVA as compared to control; * p < 0.05; ** p < 0.01;
*** p < 0.001
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increase in MMP3 confirming this response is FGFR1-
independent.
Previous studies suggest astrocytes were a potential
source of these proteins [16, 55, 70]. We therefore ana-
lyzed supernatants harvested from mouse astrocytes cul-
tured in the presence or absence of FGF2 (Fig. 4d-f).
FGF2 increased CXCL10 and TIMP1 concentrations to
levels comparable to that seen in myelinating cultures
indicating astrocytes are the major source of these
proteins. The ability of astrocytes to mediate these
FGFR1-associated responses in MS is supported by our
demonstration astrocytes in MS lesions are FGFR1+
(Fig. 4g). FGF2 treated astrocytes also secreted low
levels of MMP3, but its concentration was an order
of magnitude lower than in supernatants from myeli-
nating cultures indicating that the major source in
these cultures is some other cell type (Fig. 4e).
Taken together these observations suggest enhancing
FGFR1-dependent responses whilst suppressing signal
transduction by FGFR2 would enhance lesion repair, but
for this to be effective the detrimental effects of FGF2
on (re)myelination must be reversible. We therefore in-
vestigated the effects of withdrawing FGF2 from myeli-
nating cultures after 10 days treatment (100 ng/ml; DIV
18–28). Quantifying myelination 10 days later (DIV 38)
revealed withdrawal of FGF2 was followed by rapid mye-
lination that resulted in levels of ensheathment compar-
able to that seen in untreated control cultures (Fig. 4h-j).
Discussion
To investigate how FGF2-dependent mechanisms con-
tribute to lesion development in MS we first mapped its
expression in lesions and NAWM by in situ
hybridization and immunohistochemistry. This combin-
ation of techniques revealed astrocytes up-regulate ex-
pression of FGF2 in active lesions and the magnitude of
this response correlated with lesion activity as defined by
CD68 immune reactivity. This identified astrocytes as a
major source of FGF2 in active lesions, although acti-
vated microglia/macrophages may also contribute to
this response [18], and provides a logical explanation
why CSF concentrations of FGF2 correlate with dis-
ease activity [69, 77].
We then went on to explore how increasing FGF2
availability may influence lesion development, focusing
on understanding how this single mediator not only
modulates oligodendrogenesis and myelination, but also
mediates neuroprotection [3, 66, 68]. Previous studies
provide compelling evidence this is determined at least
in part by cell specific differences in FGFR expression [4,
25]. We therefore investigated the effect of restricting
signaling to FGFR1 in myelinating cultures that replicate
the cellular complexity of the CNS parenchyma in which
FGFR1 is expressed by multiple cell types (astrocytes
> > OPC > neurons > microglia) [90]. This strategy not
only dissociated the mitogenic potential of FGF2 from
its inhibitory effects on myelination, but also provided a
tool that allowed us to define how specific FGFRs con-
tribute to the functional outcome of FGF2 signaling in
the CNS. This revealed inhibition of myelination by
FGF2 is dependent on FGFR2 mediated activation of
Wnt signaling; pharmacological inhibition of Wnt sig-
naling being sufficient to suppress inhibition of myelin-
ation by FGF2. It should be noted inhibiting Wnt
signaling had no significant effect on progenitor cell pro-
liferation, which is in agreement with our observation
this is driven primarily via activation of FGFR1. Cross-
talk between FGF and Wnt signaling is well documented
in other settings [45, 83, 86] and we suspect this occurs
at the level of GSK3β, a major component of the β-
catenin destruction complex, which is modulated in
response to FGFR-mediated activation of PI3K/Akt sig-
naling [46]. We anticipate this is an oligodendrocyte
intrinsic response as terminally differentiated oligoden-
drocytes not only express high levels of FGFR2, but Wnt
signaling is also activated in cells of the oligodendrocyte
Table 1 qPCR validation for immunoregulatory/neuroprotective genes
Gene qPCR validation




FGF2 F2 V2 FGF2 F2 V2
Cd93 240.2 ± 101.2 (***) 44.9 ± 9.1 (***) 74.1 23.8 CATCTCACTCTTGCTGGCTCT TCTCCTCTTTCTTGGCTTTCC
Il11 48.4 ± 19.8 (***) 14.9 ± 3.7 (**) 47.5 6.3 CTCCCCTCGAGTGTCTTCAG CCATCAGCTGGGAATTTGTC
Hb-egf 22.2 ± 12.0 (***) 7.1 ± 2.5 (**) 11.9 4.9 TTTCTCCTCCAAGCCACAAG TTCCTCTTCTTTTTCCCGTTC
Lif 13.6 ± 4.6 (***) 3.8 ± 1.7 (*) 19.4 4.0 CCTTCCCATCACCCCTGT CGTTGAGTTGAGCCAGTTGA
Cxcl1 12.5 ± 4.1 (***) 8.4 ± 1.8 (***) 4.0 5.6 AACCGAAGTCATAGCCACACTC CACCCTTTAGCATCTTTTGGAC
Timp1 6.2 ± 0.9 (**) 5.8 ± 1.8 (**) 2.8 2.3 CTGGTTCCCTGGCATAATCT ATCGCTCTGGTAGCCCTTCT
Mmp13 28.6 ± 14.0 (***) 2.2 ± 1.8 (ns) 28.1 1.2 CTGCGGTTCACTTTGAGGA GAGGCGGGGATAGTCTTTGT
Mmp3 8.1 ± 3.5 (*) 0.4 ± 1.2 (ns) 6.8 −1.0 CCCGTTTCCATCTCTCTCAA GACATCAGGGGATTCTGTGG
Shown are mean +/− SEM of at least 5 independent experiments; p-values for ΔCt of Control vs FGF2 or F2 V2 respectively (one-way ANOVA, Holm-Sidak post-
test); * p < 0.05, ** p < 0.01, *** p < 0.001, ns - not significant
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Fig. 4 FGFR1 supports induction of pro-myelinating and neuroprotective factors. Mouse myelinating cultures were treated with 100 ng/ml FGF2
or F2 V2 at DIV18 for 3 days and protein levels in the cell culture supernatant were analyzed by ELISA for CXCL1 (a) and TIMP1 (b) or by Proteom
Profiler (c, Mouse Cytokine Array Panel a). a, b FGF2 treatment results in a significant increase in protein levels for both CXCL1 and MMP3 (p <
0.05), whereas F2 V2 only significantly increased the levels of CXCL1. Data are presented as means + SEM from 6 independent experiments; * p <
0.05. c TIMP1 levels are increased in both FGF2 and F2 V2 treated cultures; data are presented as technical duplicates from 2 independent
experiments, pixel densities are represented as arbitrary units. d-f A monolayer of neurosphere-derived mouse astrocytes was treated with 100
ng/ml recombinant FGF2 for 3 days and concentrations of CXCL1 (d), MMP3 (e) or TIMP1 (f) were determined by ELISA (d, e) or Proteom Profiler
(f, Mouse Cytokine Array Panel a). d, e Data are presented as means ± SEM from 4 independent experiments; * p < 0.05; ** p < 0.01 (paired t-test),
f Data are presented as technical duplicates from 2 independent experiments, arbitrary units represent pixel densities. g FGFR1 expression co-
localizes with GFAP+ astrocytes in active multiple sclerosis. h, i Myelinating CNS cultures were treated in the absence or presence of 100 ng/ml
FGF2 for 10 days from DIV 18 onwards and either directly fixed and stained for MOG / SMI31 after a total of 28 days (28 DIV) or after 38 days
in vitro (38 DIV); shown are mean + SEM from at least 4 independent experiments and p-values for paired t-test; * p < 0.05. j Representative
confocal immunofluorescence images (63x magnification, Maximum Intensity Projection) of 38 DIV culture demonstrating withdrawal of FGF2 (18
DIV – 28 DIV) is followed by rapid remyelination resulting in the formation of myelinated internodes that are indistinguishable from those in
untreated cultures. Scale bars represent 10 μm
Thümmler et al. Acta Neuropathologica Communications           (2019) 7:212 Page 11 of 15
lineage in MS lesions [23]. However, we have not for-
mally excluded the possibility “off target” effects trig-
gered by FGFR2 mediated activation of Wnt in other
cells contribute to inhibition of myelination by FGF2.
Additional studies using human oligodendrocytes are
therefore required to validate this hypothesis and to de-
termine the relative importance of downstream pathways
associated with FGFR signal transduction, in particular
extracellular signal-regulated protein kinase (ERK)/mito-
gen-activated protein kinase (MAPK) pathway and
PI3K/Akt/mechanistic target of rapamycin (mTOR)
pathways which are known to modulate oligodendrocyte
differentiation and myelination [20, 29, 30, 32, 36, 44].
These observations are important as they identify
FGF2 as a factor up-regulated in active MS lesions that
disrupts myelination via activation of Wnt, a pathway
which plays important roles in regulating myelination
and remyelination, and is dysregulated in MS [23, 37,
82]. However whilst FGFR2 dependent inhibition of
(re)myelination may be one biological outcome of in-
creasing FGF2 availability in the CNS, this is accompan-
ied by a host of FGFR1-dependent responses predicted
to enhance lesion repair. Activation of FGFR1 is not only
directly mitogenic for OPC, but also induces expression
of pro-myelinating and immunomodulatory factors by
other cell types. These include pro-myelinating factors
predicted to promote OPC proliferation, migration and/
or survival (IL-11, LIF, CXCL1, TIMP1, HB-EGF) and
others with immunomodulatory and/or neuroprotective
properties (CD93, IL-11, LIF; HB-EGF) predicted to re-
strain inflammatory activity in the CNS [13, 24, 38, 42,
55, 56, 64, 91]. Conversely, skewing signaling to favor
FGFR1 also prevents the ability of FGF2 to induce
MMPs implicated in blood-brain barrier damage and
leucocyte recruitment in multiple sclerosis and other
neurological diseases [31, 65, 88, 89].
We propose this concatenation of FGFR1-dependent
effects are responsible for the neuroprotective potential
of FGF2 in EAE [66], but the relative importance of
FGFR1-dependent responses in different cell type re-
mains unclear. FGFR1 expression in oligodendrocytes is
reported to suppress disease activity in EAE [61] and en-
hance remyelination following chronic cuprizone medi-
ated demyelination [92]. However these interpretations
should be treated with caution as tamoxifen was used to
ablate expression of FGFR1 in these studies. Tamoxifen
not only suppresses disease activity in EAE [6], but also
accelerates repair of demyelinated lesions in vivo [34].
Future studies investigating the functional significance of
cell type specific activation of FGFR1 signaling pathways
in animal models of MS must take these confounding is-
sues into account.
To the best of our knowledge this is the first demon-
stration an FGFR1-specific agonist can be used to
uncouple the detrimental effects of FGF2 on myelination
from its ability to induce a broadly neuroprotective
signaling environment. This raises the interesting possi-
bility, that CNS delivery of FGFR1 specific agonists such
as F2 V2 may provide a novel strategy to induce neuro-
protection without compromising (re)myelination. A
concept consistent with expression of FGFR1 by astro-
cytes, Olig2+ progenitors and occasional neurons in the
CNS ([17, 90], and this study), although selective deliv-
ery of therapeutic agents into the CNS remains a major
challenge [5].
In summary we demonstrate FGF2 expression is up-
regulated by astrocytes in inflammatory MS lesions
where it may contribute to remyelination failure, whilst
simultaneously providing a neuroprotective signaling en-
vironment. These diametrically opposed functions can
be uncoupled by polarizing FGFR activation to favor
FGFR1 which retains the mitogenic activity of FGF2 and
its ability to induce expression of neuroprotective, pro-
myelinating and anti-inflammatory factors in the
absence of a detrimental effect on myelination. We
propose FGFR1 selective agonists may provide a general-
ized strategy to reduce tissue damage and accelerate le-
sions repair in inflammatory and ischaemic CNS
diseases.
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